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1. Introduction 
Modern advances in the chemistry of the glycosidic 
linkage make the total synthesis of blood-group anti- 
genie determinants a realistic challenge. It was very 
recently taken up by Lemieux and Driguez [ 1,2] 
and by Jacquinet and Sinaj; [3] who described for 
the first time the step by step synthesis of reducing 
trisaccharides carrying B, H and Lewis a specificities. 
In addition, a ‘synthetic’ antigen related to the 
human blood-group Lewis a was obtained by 
L.emieux et al. [4], after attachment of the oligo- 
saccharide to high molecular weight substances. 
As demonstrated with oligosaccharides found in 
minute amounts in natural sources or obtained by 
various degradations of blood-group substances, 
these products are useful for biochemical purposes 
such as hapten inhibition [S-7], affinity chromato- 
graphy [8-l 01, raising of antibodies in animals 
[4,1 l] or substrate specificity studies of glyco- 
sidases [5,6,12] and blood-group gene glycosyl- 
transferases [13-l 61. 
Although ABH oligosaccharides conjugated to 
solid carriers will be of prime importance in the 
future for the large scale production of specific 
antisera, the reducing compounds are useful for 
inhibition and enzymatic studies. 
* Correspondance: P. Sinaj;, Orleans, France. 
In this work synthetic H substances [3], namely 
the 2’-fucopyranosyl-N-acetyllactosamine (2’FLNAc) 
and the 2’-fucosylgalactose (2’FG), were submitted 
to agglutination inhibition and enzymatic studies. 
2. Materials and methods 
UDP-N-acetyl-D-[ l-C’4]galactosamine (49.5 mCi/ 
mmole) and UDP-D- [ l-‘4]galactose (281.5 mCi/ 
mmole) were purchased from Nen Chemicals (Frank- 
furt) and respectively used in 50% and 2% ethanolic 
solutions. 
2’Fucosyllactose (2’FL): O-cr-L-fucopyranosyl 
(l-+2)-U-p-D-galactopyranosyl-( l-+4)-D-glucopyranose, 
was extracted from selected human milk. 
2’Fucosylgalactose (2’FG): U+L-fucopyranosyl- 
(1+2)-D-galactopyranose and 2’fucopyranosyW 
acetyllactosamine (2’FLNAc): U-LY-L-fucopyranosyl- 
(1 -t2)-O;O-D-galactopyranosyl( l-+4)-N-acetyl-D- 
glucosamine were chemically synthesised [3 1. 
Serum samples from A,, AZ, B and 0 blood-groups 
donors were collected and stored at -80°C until 
used for glycosyltransferase assays. 
The serological reactivities of the low molecular 
weight acceptors: 2’FG, 2’FL and 2’FLNAc have 
been tested by haemagglutination inhibition of 
appropriate blood-group systems (A, B, H and Lewis) 
in microtiter plates [ 171: ten microliters of a specific 
antibody or lectin dilution (human anti-A: l/64; 
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human anti-B: l/S 12; anti-H from Ulex eut~~pucus 
l/2: anti-H from Bombay individual: l/32; human 
anti-LeX: l/4; eel serum: l/256; and Lotus 
tetragunolohus extract: l/2), were carefully mixed 
10 ~1 or serial dilutions of inhibitors and incubated 
1 hat room temperature. Twenty microliters of 
0.5% RBC suspensions (A*, B, 0, L,e(a+) and Le(b+) 
RBC’s) were then added and the agglutination reaction 
rea’d microscopically after standing 16 h at 4°C. The 
degree of inhibition was expressed as the minimum 
amount of substance (pg in 40 ~1) giving complete 
inhibition of the systems. 
2.2. Enzyme assays 
oc-N-acetylgalactosaminyltransferase ctivities 
were directly measured on whole sera, in a mixture 
containing the following components to a total 
volume of 45 ~1: Mn*+ 2.0 pmol; sodium cacodylate 
buffer pH 6 or pH 7, 2.0 ,umol; 2’FL, 0.28 /_miol or 
2’FG, 0.37 lmol, or 2’FLNAc, 0.23 pmol; ATP, 
0.2 pmol; [ l-‘4C]UDPGalNAc, 1 .O nmol (E 75 000 
cpm); serum, 10 ~1. 
cu-D-galactosyltransferase activities were performed 
in a mixture containing under 50 ~1 total volume: 
Mn’+, 1 .O /~mol; sodium cacodylate buffer pH 6.5, 
2.0 kmol; 2’FL, 0.41 pm01 or 2’FG, 0.74 pmol, or 
2’FLNAc, 0.46 pmol; ATP, 0.5 pmol; serum, 10 ~1; 
[14C]UDPGal, 0.23 nmol (= 90 000 cpm). After 
standing 18 h at 37”C, the synthesised neutral 
saccharides were separated from unreacted UDP- 
sugars by high voltage electrophoresis in 0.1 M 
ammonium formiate buffer pH 3.5 (Whatman 
paper no 40; 3000 V/200 mA). 
Free [l-‘4C]GalNAc or [14C]Cal released 
during incubation process were eliminated by 
descending chromatography in solvent h and the 
radioactive saccharides were then detected on a 
radiochromatogram scanner (Packard, 7201) and 
estimated by liquid scintillation counting (Nuclear 
Chicago, Mark II). 
2.3. Churacterisation of producls by paper 
chromatography 
The A and B active saccharides ynthesised 
after enzyme assays were eluted from Whatman 40 
paper strips in lactose 8.10m6 M, desalted on 
Biodeminrolit, (14~-52 mesh, Hopkin and Willians) 
previously equilibrated with lactose 10 mM, 
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concentrated under vacuum and submitted to 
descending paper chromatography (Whatman 40) 
in the following solvents: solvent a: ethyl acetate-- 
pyridinc-water (2 : 1 : 2), upper phase, solvent b: 
ethyl acetate---pyridine-acetic acid-water (5 : 5 : 1 : 3). 
The mobility of each compound has been 
expressed as RL.ac, in terms of the mobility compared 
to a reference solution of lactose. 
3. Results 
3.1. Synthesis and properties of 2’FLNAc and 2’1% 
The synthesis of 2’FLNAc was performed by 
using benzyl ethers as temporary blocking groups of 
hydroxylic functions. Benzyl2-acetamido-3,6-di-0 
benzyl-2-deoxy-cw-D-glucopyranoside [ 181 was first 
glycosylated by 3, 4, 6-tri-0benzyl-1,2-O- (tert- 
butoxyethylidenej-cu-D-galactopyranose. After 
0deacetylation, the obtained compound was 
glycosyldted by 2, 3,4-tri-0-benzyl-cw-L-fucopyranosyl 
bromide [19] using the bromide ion catalysed 
reaction [20]. 2’FLNAc was obtained after hydrogeno- 
lysis as a pure amorphous powder, [c~]g = --46S”C 
(c 0.5, HZO), RLac = 1 .OO (ethyl acetate-pyridine- 
water, 10 : 4 : 3). 
2’FG was synthesised by glycosylation of benzyl 
3,4, G-tri-O-benzyl-/3-D-galactopyranoside with 2, 3, 
4-tri-0-benzyl-cw-L-fucopyranosyl bromide, using the 
bromide ion catalysed reaction. [CY~ = -56°C (c 1.2, 
H,O), RL.ac = 1.58 (ethyl acetate-pyridine--water, 
10 : 4 : 3). These properties are in close agreement 
with those previously reported [21]. 
3.2. Serological activity of the synthetic sugars 
2’FG and 2’FLNAc were tested in the haemag- 
glutination inhibition of A, B, H and Lewis human 
RBC by antisera or lectins with appropriate specificity. 
As shown in table 1, minimum amount of 
sugars completely inhibiting red cell agglutinability 
are reported for 2’FG and 2’FLNAc but also for 
2’FL (from human milk) and L-fucose. 
As it could be expected, no inhibition is observed 
in the A, B or Lewis systems. On the contrary, all 
these compounds inhibit the H/anti-H agglutinating 
systems but to different extent. The anti-H from 
Lottis tetragonolobus and eel serum are highly 
inhibited by the substances tested with the exception 
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Table 1 
Inhibition of haemagglutination reactions by oligosaccharides 
Inhibitors 
Structure 
Short 
name 
Minimum amount (pg/40 ~1) of substance giving complete inhibition of 
agglutination in the following systems 
Anti-H reagents 
A B Lea Leb ~~ 
human Ulex Lotus eel 
(Bh) europaeus tetragonolobus serum 
cu-L-l:uc-( l-2)Gal 2’FG >120 >120 >120 >120 >120 1.9 3.75 
a-L-Fuc (l-2) Gal p (144) GlNAc 2’FLNAc >120 >120 >120 >120 30 1.9 3.75 
__.- ____ 
cy-L-Fuc (l-+2) Gal p (1+4) Gl 2’FL >120 >120 >120 >120 35 2.2 3.87 
(from 
human 
milk) 
L-Fuc (commercial) nt nt nt nt >lOO 50 0.78 
_____ ----_ 
Abbreviations: Gal = D-galactopyranosyl; Cl = D-glucopyranose; GlNAc = N-acetyl-D-glucosamine; L-Fuc = L-fucose. 
3.75 
7.5 
---_ 
61 
3.12 
of 2’FL from human milk which apparently is a rather 
poor inhibitor of the eel serum. It has been reported 
that both 2’FL from human milk and a trisaccharide 
similar to 2’FLNAc isolated after alkaline hydrolysjs 
of blood group substances, are relatively poor 
inhibitors of eel serum as compared to 2’FG or 
Lfusoce [6]. It is assumed that the strong inhibition 
of eel serum by synthetic 2’FLNAc, come both from 
its high degree of purity and from the primary role 
of the N-acetyl residue in such activity. The presence 
of some deacetylated molecules in the 2’FLNAc 
obtained by chemical degradation together with the 
known heterogeneity of anti-H reagents [22] cannot 
be excluded and may provide a possible explanation 
to the poor inhibitory activity of such oligosaccharide 
toward eel serum [6]. 
Using an anti-H seed extract from Ulex europaeus, 
2’FG, 2’FLNAc and 2’FL are equally good inhibitors, 
while L-fucose itself is much less active. Using a human 
anti-H from a ‘Bombay’ (Bh) individual, only 2’FLNAc 
and 2’FL are found to be highly active. 2’FG and 
Lfucose are not inhibitors, probaBiy because the 
human antibody combining site has to be comple- 
mentary of an antigenic structure involving at least 
three saccharide units. Furthermore these inhibition 
studies support the proposed differences of specificities 
between the various anti-H reagents [22]. 
3.3. Glycosyltransferuse activities on low molecular 
weight acceptors 
The enzyme activities in human sera of A, (BAD. 
and ROP.), A2 (SAL. and RAH.), B (BI : RUF. ; B 
II : DOI. ; B III : KEI.) and 0 individuals were 
simultaneously tested on 2’FG, 2’FL and 2’FLNAc, 
each measurement being done in duplicate (table 2). 
Among A sera, whatever the enzyme substrate, the 
A, and AZ transferases were distinguished according 
to their expected optimum pH: 6.0 for A, samples, 
and 7.0 for A* samples [23,24]. In all cases, enzyme 
activity measurements how that among the three 
oligosaccharides used, 2’FLNAc appears to be the 
best acceptor. However it can also be demonstrated 
that 2’FG is a much poorer substrate for A2 enzymes. 
Among B sera, where one sample of each 
cu-D-galactosyltransferase group B I, B II and B III [25] 
have been tested at pH 6.5, the 2’FLNAc was also 
the most efficient acceptor, In variance with the 
result obtains with A* enzymes, 2’FG seems an equally 
good substrate for B galactosyltransferases. 
The structures of A and B reaction products 
obtained with the various acceptors have not been 
elucidated by chemical means, but were only 
identified by paper chromatography in solvents a 
and b (table 2). It then appears that RLac values 
reported for tri- and tetrasaccharides (A and B) 
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formed after enzyme assays using 2’FG and 2’FL are 
in good agreement with previously reported values 
on well characterised substances (14,2627). On the 
other hand, A and B tetrasaccharides derived from 
2’FLNAc are similar to the structures isolated by 
alkaline degradation of human A and B ovarian 
cyst glycoproteins [28]. 
4. Conclusions 
Chemically synthesised 2’fucosylgalactose 
(2’FG) and 2’fucosyl-N-acetyllactosamine (2’FLNAc) 
can be obtained in pure form on a gram scale. 
These compounds retain their biochemical 
properties when evaluated by haemagglutination 
inhibitions and substrate specificity for glycosyl- 
transferases, studies which support their high degree 
of purity established by chemical analysis. 
Considering that substrates are not the limiting 
factors, 2’FLNAc appears to be an even better 
acceptor for A and B blood-group enzymes than 
2’FL, usually extracted from human milk and in 
which glucose is the terminal reducing sugar. 
However, the differences between acceptors are 
very small especially with cY-D-galactosyltransferase, 
possibly because the catalytic site of this enzyme 
is of more restricted area. On the contrary, 2’FG is 
approximatively three times less efficient than 
2’FLNAc in assays of AZ serum enzymes, such a 
difference being not observed with AI enzymes. 
However, the actual difference between A, and 
AZ blood types is still not clear, even if, as far as 
serum enzymes are concerned, A, and A2 transfe- 
rases can be distinguished according to their kinetic 
properties on low molecular weight acceptors or in 
enzymic conversion of 0 RBC into A RBC [23,24,29]. 
Furthermore, the A, and AZ enzymes act on type 1 
(LNF-I) and type 2 (2’FG, 2’FL, 2’FLNAc) low 
molecular weight acceptors, but AZ serum trans- 
ferases exhibit higher KM values than A, serum 
enzymes do. 
Keeping in mind first that A, and AZ specificities 
are easily recognized on red cells but not clearly in 
secreted glycoproteins [30-321 and secotidly that 
only ABO fucolipids containing type 2 chains have 
been isolated from human red cell stroma [33] , it 
became likely that reasons to explain A, and A2 
specificities should not be based on the existence 
of type 1 chains in blood-group substances [34]. At 
the biochemical level, Hakomori et al. 1351 have 
also shown that A glycolipids are highly polymorphic, 
four antigenic structures A”, Ab, AC and Ad being 
isolated from A, RBC. If only trace amounts of the 
branched glycolipids AC and Ad are found in A2 RBC 
membranes [36], it can be postulated that A, 
enzymes should be able to convey N-acetylgalactos- 
amine on linear and branched precursors with H 
specificity, whereas A2 enzymes should only act 
on simplest non-ramified H precursors. 
The demonstration of such hypothesis needs 
further investigations using macromolecular H 
acceptors, such as described by Stellner et al. [37] 
and Watanabe et al. [38]. Development of 
synthetic determinants would therefore be also 
of a considerable value in this field. 
Finally it becomes obvious that A, and AZ gene 
products identified in human sera have distinct 
properties, a fact which is further supported by 
recent estimations of their isoelectric points: pH, = 
10 (A, sera) or pHi = 6.2 (A? sera) [39]. However, 
properties of Al and A2 transferases partially 
purified from plasma are claimed to be similar [40], 
an observation to be joined to the identical isoelectric 
points of these gene products in ovarian cyst fluids 
[38] (Al and A2 enzymes, pHi = 9.5 to 10). 
It is therefore to be investigated whether or not 
properties of transferases evaluated on whole sera do 
represent true characteristics of Al and AZ gene- 
products. 
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